Q&A about managing sicca in Sjogren's here:
www.themednet.org/v2/programs/...
14/15
Q&A about managing sicca in Sjogren's here:
www.themednet.org/v2/programs/...
14/15
First up? The novel CD40L inhibitor in #Sjogren's. Scouting report by #DukeRheum.
More in 🧵👇 (1/15)
First up? The novel CD40L inhibitor in #Sjogren's. Scouting report by #DukeRheum.
More in 🧵👇 (1/15)
Check out the scouting reports for the B-Cell Breakaway Region, including:
-Obinutuzumab for #Lupus nephritis
-CD19 CAR T cells in #Rheumatology
-STRAP Trials on biopsy-guided Rx
Scouting reports 👇
sites.duke.edu/rheummadness/
Check out the scouting reports for the B-Cell Breakaway Region, including:
-Obinutuzumab for #Lupus nephritis
-CD19 CAR T cells in #Rheumatology
-STRAP Trials on biopsy-guided Rx
Scouting reports 👇
sites.duke.edu/rheummadness/
Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes
#LupusNephritis #RheumSky #NephSky #MedSky #Lupus
Phase 3 RCT: Obi vs PBO
🫘 Pts w/ SLE nephritis Class III/IV ± 5
🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids)
📊 Obi: ⇡rate of renal response and improved renal outcomes
#LupusNephritis #RheumSky #NephSky #MedSky #Lupus
Thanks to @sambhawanabhandari.bsky.social and the fellows from @washumedrheum.bsky.social for their fantastic scouting report! And thank you to @laceyfeigl.bsky.social for making it all happen!
www.buzzsprout.com/1465681/epis...
Thanks to @sambhawanabhandari.bsky.social and the fellows from @washumedrheum.bsky.social for their fantastic scouting report! And thank you to @laceyfeigl.bsky.social for making it all happen!
www.buzzsprout.com/1465681/epis...
This region explores cost-effective HCQ screening, optimal prednisone dosing in SLE, and better GCA detection.
Check it out here 👇
sites.duke.edu/rheummadness/
This region explores cost-effective HCQ screening, optimal prednisone dosing in SLE, and better GCA detection.
Check it out here 👇
sites.duke.edu/rheummadness/
In this episode:
-Q&As from theMednet.org
-Primer on T-cell co-stimulation
-Analysis of APIPPRA
-Interview with lead author of DAZ study
To listen 👇
www.buzzsprout.com/1465681/epis...
In this episode:
-Q&As from theMednet.org
-Primer on T-cell co-stimulation
-Analysis of APIPPRA
-Interview with lead author of DAZ study
To listen 👇
www.buzzsprout.com/1465681/epis...
Each team is paired with high-yield Q&As like:
-Approach to sicca
-Approach to pre-RA
-T vs. B-cell therapies in refractory SLE
See link 👇
www.themednet.org/v2/programs/...
Each team is paired with high-yield Q&As like:
-Approach to sicca
-Approach to pre-RA
-T vs. B-cell therapies in refractory SLE
See link 👇
www.themednet.org/v2/programs/...
Scouting reports for the first region (T'd Up T-Cells) have been posted, along with accompanying Q&As from theMednet.org and two new podcast episodes!
Full details 👇
sites.duke.edu/rheummadness/
Scouting reports for the first region (T'd Up T-Cells) have been posted, along with accompanying Q&As from theMednet.org and two new podcast episodes!
Full details 👇
sites.duke.edu/rheummadness/